Autonomix Medical Secures New U.S. Patent To Boost Minimally Invasive, Nerve-Targeted Treatments For High-Need Conditions

Autonomix Medical, Inc., a company focused on developing precision nerve-targeted medical devices, has announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,295,646. The patent, titled “Smart Torquer and Methods for Using the Same,” covers a smart torquer device that improves the manipulation of elongated intravascular devices during minimally invasive procedures. The innovation integrates electronic components to support both mechanical control and data communication, enhancing usability and functionality during complex vascular navigation.

The newly issued patent describes a system that includes several key features. These include an engaging mechanism that securely connects to an intravascular device, a communication module that allows for data exchange between systems, and an electrical interface designed to transmit signals. The device also includes a manipulator that enables clinicians to apply torque to guide the engaged instrument through the vascular system. This combination of mechanical control with smart communication aims to improve precision and efficiency during procedures.

Brad Hauser, CEO of Autonomix, mentioned, “This patent strengthens our intellectual property portfolio and reinforces our commitment to developing differentiated technologies that address large and underserved markets. The smart torquer improves control and signal integration for intravascular procedures, which is essential for expanding our platform into high-growth areas like cardiology, neurosurgery, and interventional radiology. With the addition of this ‘646 patent to our over 80 issued patents, Autonomix is building a defensible position in a multi-billion-dollar opportunity where precision nerve-targeted interventions can reshape clinical outcomes.”

Autonomix’s broader technology platform centers around a catheter-based microchip sensing array antenna, which is designed to detect and differentiate neural signals with heightened sensitivity compared to current technologies. This ability to accurately sense target nerves is a crucial part of the company’s strategy. Once the nerves are identified, Autonomix’s proprietary radiofrequency (RF) ablation system is used to eliminate them. 

This enables a highly targeted approach described as “sense, treat, and verify,” which may be applied to a range of conditions, including chronic pain, hypertension, and cardiovascular diseases. This new patent further strengthens Autonomix Medical’s intellectual property portfolio and supports its mission to bring innovative, nerve-targeted treatment solutions to the medical field.